Moleculin Biotech (0K2H) Stock Overview

A late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. More details

0K2H fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Does not have a meaningful market cap ($5M)

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

+ 1 more risk

0K2H Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,126 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

479,126 investors already sharing narratives

View all narratives

Moleculin Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Moleculin Biotech
Historical stock prices
Current Share Price	US$0.80
52 Week High	US$19.25
52 Week Low	US$0.80
Beta	1.75
1 Month Change	-69.47%
3 Month Change	-68.25%
1 Year Change	-94.82%
3 Year Change	-99.68%
5 Year Change	n/a
Change since IPO	-99.90%

Recent updates

Shareholder Returns

	0K2H	GB Biotechs	GB Market
7D	-62.8%	-0.7%	1.2%
1Y	-94.8%	-6.2%	19.4%

Return vs Industry: 0K2H underperformed the UK Biotechs industry which returned -5.5% over the past year.

Return vs Market: 0K2H underperformed the UK Market which returned 19% over the past year.

Price Volatility

Is 0K2H's price volatile compared to industry and market?
0K2H volatility
0K2H Average Weekly Movement	18.8%
Biotechs Industry Average Movement	7.0%
Market Average Movement	5.2%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0K2H's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0K2H's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2015	17	Wally Klemp	moleculin.com

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers.

Moleculin Biotech, Inc. Fundamentals Summary

How do Moleculin Biotech's earnings and revenue compare to its market cap?
0K2H fundamental statistics
Market cap	US$5.44m
Earnings (TTM)	-US$42.37m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is 0K2H overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0K2H income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$42.37m
Earnings	-US$42.37m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-7.94
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0K2H perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 05:02
End of Day Share Price	2026/07/31 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moleculin Biotech, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sara Nik	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group
Kevin DeGeeter	Oppenheimer & Co. Inc.

Moleculin Biotech (0K2H) Stock Overview

Risk Analysis

Join community and earn perks

Moleculin Biotech, Inc. Competitors

Theracryf

Verici Dx

CRISM Therapeutics

OptiBiotix Health

Price History & Performance

Recent News & Updates

Moleculin Biotech Reports Positive Interim Data from MIRACLE R/R AML Trial with Annamycin

New major risk - Market cap size

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Moleculin Biotech Reports Positive Interim Results from Phase 2/3 Miracle Trial of Annamycin in Relapsed or Refractory Acute Myeloid Leukemia

New major risk - Share price stability

Moleculin Biotech Announces Imminent Miracle Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Recent updates

Moleculin Biotech Reports Positive Interim Data from MIRACLE R/R AML Trial with Annamycin

New major risk - Market cap size

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Moleculin Biotech Reports Positive Interim Results from Phase 2/3 Miracle Trial of Annamycin in Relapsed or Refractory Acute Myeloid Leukemia

New major risk - Share price stability

Moleculin Biotech Announces Imminent Miracle Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Biotech, Inc. Presents New Preclinical Data on Annamycin in Pancreatic Cancer

Moleculin Biotech, Inc. Hits 45 Subject Enrollment Milestone In MIRACLE Trial For Annamycin In Combination With Cytarabine For Relapsed Or Refractory Acute Myeloid Leukemia

New major risk - Market cap size

Moleculin Biotech, Inc. Announces MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Moleculin Biotech, Inc. Launches CEO Corner Platform to Share Strategic Insights

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Moleculin Biotech, Inc. Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for Treatment of Pediatric Recurrent Malignant Brain Tumors

New major risk - Market cap size

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for First First First 2026

Moleculin Biotech Receives Delisting Determination Letter from Nasdaq

New major risk - Financial position

Moleculin Biotech, Inc. Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial

Moleculin Biotech, Inc. Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Issues New Positive AML Overall Survival Data

New major risk - Negative shareholders equity

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Moleculin Biotech, Inc. Expands Phase 3 Miracle Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Moleculin Biotech, Inc., Annual General Meeting, Aug 18, 2025

Moleculin Biotech Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.943492 million.

Moleculin Biotech, Inc. Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

New major risk - Market cap size

Moleculin Biotech, Inc. Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5550(b)(1)

New major risk - Financial position

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin Biotech, Inc. to Report Q1, 2025 Results on May 13, 2025

Moleculin Biotech, Inc. Announces World Health Organization Approval of Naxtarubicin as International Non-Proprietary Name for Annamycin

Moleculin Biotech, Inc. Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Biotech, Inc. Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Biotech, Inc. Receives US Institutional Review Board Approval for Pivotal, Adaptive Phase 3 Clinical Trial

Moleculin Biotech, Inc. to Report Fiscal Year 2024 Results on Mar 21, 2025

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $3.49788 million.

Moleculin Biotech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $20 million.

Moleculin Biotech, Inc. Receives Positive FDA Guidance for Acceleration of its Registration-Enabling Miracle Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. Receives First Country Approval in Europe to Begin Recruiting for the Miracle Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

New major risk - Shareholder dilution

Moleculin Biotech, Inc. Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

High number of new and inexperienced directors

New major risk - Shareholder dilution

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

New major risk - Financial position

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size